IP Library Granted Patent US 7,709,209
Granted Patent B2
US 7,709,209 · App. 11/363,078 · Granted May 4, 2010

Protein ligands

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,709,209
App. No.
11/363,078
Granted
May 4, 2010
Kind
B2
Abstract

The present invention relates to the use of an alkali-stable protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine.

Claims (9)

1. In a method of separating antibodies from proteases, which method comprises

(a) contacting a liquid comprising antibodies and protease(s) with a separation matrix to adsorb antibodies;

(b) separating the liquid comprising protease(s) from the matrix; and optionally,

(c) releasing the antibodies from the matrix by adding an eluent;

the improvement being that the separation matrix comprises alkali-stable protein A-based ligands which provide increased resistance of said alkali-stable protein A-based ligands to protease degradation, wherein each of said alkali-stable protein A-based ligands is represented by SEQ ID NO: 1 or SEQ ID NO: 2, with one or two asparagine residues mutated, and the mutation is N23T; N23T, N43E; N28A; N6A; N11S; N11S, N23T; or N6A, N23T, further wherein said antibodies being separated are selected from the group consisting of IgG, IgA and IgM.

2. The method of claim 1 , wherein the alkali-stable protein A-based ligands comprise at least one B domain of Protein A (SEQ ID NO: 1) in which at least one asparagine residue has been mutated as defined in claim 1 .

3. The method of claim 1 , wherein the alkali-stable protein A-based ligands comprise at least one Protein Z domain of SEQ ID NO: 2 in which at least one asparagine residue has been mutated as defined in claim 1 .

4. The method of claim 1 , wherein the alkali-stable protein A-based ligands are multimers of two or more mutated Protein Z domains of SEQ ID NO: 2, wherein in each domain at least one asparagine residue has been mutated as defined in claim 1 .

5. The method of claim 1 , wherein the antibodies are monoclonal antibodies.

Assignments (3)
CHANGE OF NAME Recorded Oct 5, 2020
From: GE HEALTHCARE BIOPROCESS R&D AB
To: CYTIVA BIOPROCESS R&D AB
Reel/Frame 054299/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2016
From: GE HEALTHCARE BIO-SCIENCES AB
To: GE HEALTHCARE BIOPROCESS R&D AB
Reel/Frame 038811/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2006
From: HOBER, SOPHIA; JOHANSSON, HANS J.; BJORKMAN, TOMAS
To: GE HEALTHCARE BIO-SCIENCES AB
Reel/Frame 017603/0993 →